Company: BOLT
Filing Date: 2025-04-15
Form Type: DEF 14A
Source: 0000950170-25-054294
Chunk: 58

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-15
Form: DEF 14A
Chunk 58
---
 which any of our directors, executive officers or holders of more than five percent of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest, other than compensation arrangements which are described in “Executive Compensation.”

We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm’s-length transactions.

Investor Rights Agreement

In June 2020, we entered into an amended and restated investor rights agreement, or IRA, with certain holders of our capital stock, including investors affiliated with former members of our Board. The IRA provided such holders with certain registration rights with respect to share of our common stock, including the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. As of December 31, 2024, no holder held any registration rights under the IRA and the IRA had been terminated pursuant to its terms.

Relationship with Stanford University

In May 2015, we entered into a license agreement with Stanford University. During 2023, we made payments to Stanford of $89,700 for annual license fees and patent expense reimbursement. During 2024, we made payments to Stanford of $91,800 for annual license fees and patent expense reimbursement.

Dr. Engleman, a member of our Board until May 2024, is a professor at Stanford. Dr. Engleman is a co-inventor of some of the patents that we license from Stanford. Under Stanford’s policies, as a co-inventor Dr. Engleman is entitled to receive a share of any royalties that we pay to Stanford under the agreements with respect to the covered intellectual property. No royalty payments have been made to date.

Employment Arrangements

We have entered into offer letters with certain of our executive officers. For more information regarding these offer letters, see “Executive Compensation - Employment Arrangements.”

Consulting Agreements

We have entered into consulting agreements with certain of our former executive officers. For more information regarding these consulting agreements, see “Executive Compensation - Consulting Agreements.”

Equity Grants

We have granted options to certain of our directors and executive officers. For more information regarding the options granted to our directors and named executive officers, see “Executive Compensation” and “Director Compensation”.

<div align='center'>37</div>

Indem